Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice-Reference-Cited by-同舟云学术

Trifluridine / tipiracil (FTd / TPI, TAS-102) in the treatment of patients with metastatic colon cancer: from preclinical experiments to routine clinical practice

Published:2020-12-30 Issue:3-4 Volume:10 Page:11-26
ISSN:2686-9594
Container-title:Pelvic Surgery and Oncology
language:
Short-container-title:Onkol. koloproktol.

Author:

Fedyanin M. Yu.¹^ORCID

Affiliation:

1. N. N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; Peoples’ Friendship University of Russia; City Clinical Hospital No. 40, Moscow Healthcare Department

Abstract

The development of new treatment options gradually brings metastatic colon cancer closer to a chronic disease that can last for years. One of such options is trifluridine / tipiracil (FTD / TPI, TAS-102), a new chemotherapeutic agent, which has already been registered in more than 60 countries. It increases patients’ survival and has an acceptable toxicity profile (adverse events primarily include hematological complications). This literature review aims to cover various aspects related to this new drug, including its pharmacokinetics, maximum tole rated dose, possibility of its use in patients with liver disorders, results of its simultaneous use with targeted therapy, comparison with other therapeutic approaches in patients with chemorefractory metastatic rectal cancer, etc.

Publisher

Publishing House ABV Press

Subject

General Medicine,Automotive Engineering

Reference121 articles.

1. Chiang C.L., Choi H.C., Lam K.O. et al. Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. Asia-Pac J Clin Oncol 2019;1–9.

2. Emura T., Suzuki N., Fujioka A. et al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the coadministration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol 2005;27:449–55.

3. Dexter D.L., Wolberg W.H., Ansfield F.J. et al. The clinical pharmacology of 5-trifluoromethyl-20-deoxyuridine. Cancer Res 1972;32:247–53.

4. Fukushima M., Suzuki N., Emura T. et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 20-deoxyribonucleosides. Biochem Pharmacol 2000;59:1227–36.

5. Salonga D., Danenberg K.D., Johnson M. et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322–7.